CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Lanreotide

兰瑞肽 杂质对照品Lanreotide Impurities

20 个杂质条目20 impurity entries

本页汇总 兰瑞肽 的 20 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 20 impurity reference standards of Lanreotide. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 兰瑞肽(Lanreotide)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 分析方法Analytical MethodsSol-gel Carbowax 20M-zwitterionic ionic liquid composite sorbent-based capsule phase microextraction device combined with HPLC/post-column derivatization for the determination of lanreotide, a human somatostatin analogue in urine
    Journal of chromatography. A · 2024 · Ntorkou M et al.  ·  PMID 38290172  ·  DOI
  2. 分析方法Analytical MethodsA New Approach to Supramolecular Structure Determination in Pharmaceutical Preparation of Self-Assembling Peptides: A Case Study of Lanreotide Autogel
    Pharmaceutics · 2022 · Grimaldi M et al.  ·  PMID 35336055  ·  DOI
  3. 分析方法Analytical MethodsBioanalysis of lanreotide in dog plasma using liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study of beagle dogs after single subcutaneous injection
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2022 · Kim T et al.  ·  PMID 34891048  ·  DOI
  4. 分析方法Analytical MethodsTherapeutic 188Re-lanreotide: determination of radiopharmacokinetic parameters in rats
    The Journal of pharmacy and pharmacology · 2010 · Molina-Trinidad EM et al.  ·  PMID 20604834  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisDirect synthesis of ultralong platinum nanowires with prominent electrocatalytic performance using lanreotide biotemplate
    Nanotechnology · 2019 · Bian K et al.  ·  PMID 30523961  ·  DOI

兰瑞肽 —— 原料药与杂质对照品Lanreotide — drug substance & impurities

共 21 个条目(含原料药本体)21 items incl. the drug substance
Lanreotide structure
原料药 APIAPI
兰瑞肽Lanreotide
Lanreotide
CAS No.108736-35-2
Chemical FormulaC54H69N11O10S2
Purity>95%询价On request
10mg25mg50mg100mg
Lanreotide Impurity 1 structure
1
兰瑞肽杂质1Lanreotide Impurity 1
Lanreotide Impurity 1
CAS No.1353092-24-6
Chemical FormulaC56H71N11O11S2
Purity>95%询价On request
10mg25mg50mg100mg
Lanreotide Impurity 2 structure
2
兰瑞肽杂质2Lanreotide Impurity 2
Lanreotide Impurity 2
CAS No.243470-19-1
Chemical FormulaC54H69N11O10S3
Purity>95%询价On request
10mg25mg50mg100mg
Lanreotide Impurity 5 structure
5
兰瑞肽杂质5Lanreotide Impurity 5
Lanreotide Impurity 5
CAS No.109605-17-6
Chemical FormulaC56H71N11O11S2
Purity>95%询价On request
10mg25mg50mg100mg
Lanreotide Impurity 6 structure
6
兰瑞肽杂质6Lanreotide Impurity 6
Lanreotide Impurity 6
CAS No.1353092-18-8
Chemical FormulaC55H71N11O10S2
Purity>95%询价On request
10mg25mg50mg100mg
Lanreotide Impurity 8 structure
8
兰瑞肽杂质8Lanreotide Impurity 8
Lanreotide Impurity 8
CAS No.150155-56-9
Chemical FormulaC54H68N10O11S2
Purity>95%询价On request
10mg25mg50mg100mg
Lanreotide Impurity 12 structure
12
兰瑞肽杂质12Lanreotide Impurity 12
Lanreotide Impurity 12
CAS No.76985-10-9
Chemical FormulaC18H21NO4
Purity>95%询价On request
10mg25mg50mg100mg
Lanreotide Impurity 19 structure
19
兰瑞肽杂质19Lanreotide Impurity 19
Lanreotide Impurity 19
CAS No.247032-78-6
Chemical FormulaC41H58N10O9S2
Purity>95%询价On request
10mg25mg50mg100mg
Lanreotide Impurity 20 structure
20
兰瑞肽杂质20Lanreotide Impurity 20
Lanreotide Impurity 20
CAS No.131836-60-7
Chemical FormulaC54H68IN11O10S2
Purity>95%询价On request
10mg25mg50mg100mg
Lanreotide Impurity 24 structure
24
兰瑞肽杂质24Lanreotide Impurity 24
Lanreotide Impurity 24
CAS No.113294-82-9
Chemical FormulaC54H71N11O10S2
Purity>95%询价On request
10mg25mg50mg100mg
Lanreotide Impurity 25 structure
25
兰瑞肽杂质25Lanreotide Impurity 25
Lanreotide Impurity 25
CAS No.113294-85-2
Chemical FormulaC56H73N11O11S2
Purity>95%询价On request
10mg25mg50mg100mg
Lanreotide Impurity 26 structure
26
兰瑞肽杂质26Lanreotide Impurity 26
Lanreotide Impurity 26
CAS No.215717-91-2
Chemical FormulaC49H60N10O9S2
Purity>95%询价On request
10mg25mg50mg100mg
Lanreotide Impurity 27 (D-Cys7 Lanreotide) structure
27
兰瑞肽杂质27 (D-半胱氨酸7 兰瑞肽)Lanreotide Impurity 27 (D-Cys7 Lanreotide)
Lanreotide Impurity 27 (D-Cys7 Lanreotide)
CAS No.205234-53-3
Chemical FormulaC54H69N11O10S2
Purity>95%询价On request
10mg25mg50mg100mg
Lanreotide Impurity 28 structure
28
兰瑞肽杂质28Lanreotide Impurity 28
Lanreotide Impurity 28
CAS No.1017280-17-9
Chemical FormulaC54H69N11O10S2
Purity>95%询价On request
10mg25mg50mg100mg
Lanreotide Impurity 29 structure
29
兰瑞肽杂质29Lanreotide Impurity 29
Lanreotide Impurity 29
CAS No.182494-54-8
Chemical FormulaC62H82N12O15S2
Purity>95%询价On request
10mg25mg50mg100mg
Lanreotide Impurity 30 structure
30
兰瑞肽杂质30Lanreotide Impurity 30
Lanreotide Impurity 30
CAS No.131799-89-8
Chemical FormulaC56H70IN11O11S2
Purity>95%询价On request
10mg25mg50mg100mg
Lanreotide Impurity 31 structure
31
兰瑞肽杂质31Lanreotide Impurity 31
Lanreotide Impurity 31
CAS No.778629-24-6
Chemical FormulaC63H78N12O13S2
Purity>95%询价On request
10mg25mg50mg100mg
Lanreotide Impurity 32 structure
32
兰瑞肽杂质32Lanreotide Impurity 32
Lanreotide Impurity 32
CAS No.182482-12-8
Chemical FormulaC59H77N11O12S2
Purity>95%询价On request
10mg25mg50mg100mg
Lanreotide Impurity 33 structure
33
兰瑞肽杂质33Lanreotide Impurity 33
Lanreotide Impurity 33
CAS No.108335-11-1
Chemical FormulaC59H77N11O12S2
Purity>95%询价On request
10mg25mg50mg100mg
Lanreotide Impurity 34 structure
34
兰瑞肽杂质34Lanreotide Impurity 34
Lanreotide Impurity 34
CAS No.778632-60-3
Chemical FormulaC78H99N15O17S2
Purity>95%询价On request
10mg25mg50mg100mg
Lanreotide Impurity 40 structure
40
兰瑞肽杂质40Lanreotide Impurity 40
Lanreotide Impurity 40
CAS No.209006-25-7
Chemical FormulaC56H71N11O11S2
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

兰瑞肽 —— 研究文献与合成路线Lanreotide — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 兰瑞肽 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Lanreotide. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. A New Approach to Supramolecular Structure Determination in Pharmaceutical Preparation of Self-Assembling Peptides: A Case Study of Lanreotide Autogel
    Grimaldi M, Santoro A, Buonocore M, et al. · Pharmaceutics · 2022 · 被引 9cited 9

合成路线文献Synthetic-route papers

  1. On-resin synthesis of Lanreotide epimers and studies of their structure-activity relationships
    Chowdhury A, Tripathi NM, Jadav R, et al. · RSC medicinal chemistry · 2024
  2. Direct synthesis of ultralong platinum nanowires with prominent electrocatalytic performance using lanreotide biotemplate
    Bian K, Li Y, Xue W, et al. · Nanotechnology · 2019
  3. Effect of lanreotide, a somatostatin analogue, on urea synthesis in normal man
    Wolthers T, Grøfte T, Orskov H, et al. · Clinical nutrition (Edinburgh, Scotland) · 1994

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

兰瑞肽 杂质谱研究要点Lanreotide — impurity profiling notes

下面这些是拿到 兰瑞肽 的 21 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 21 impurity entries for Lanreotide, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances